Emergent BioSolutions (EBS) Operating Income (2016 - 2025)
Historic Operating Income for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $76.5 million.
- Emergent BioSolutions' Operating Income rose 1860.47% to $76.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.5 million, marking a year-over-year increase of 18286.71%. This contributed to the annual value of -$108.7 million for FY2024, which is 8503.58% up from last year.
- Per Emergent BioSolutions' latest filing, its Operating Income stood at $76.5 million for Q3 2025, which was up 1860.47% from $1.6 million recorded in Q2 2025.
- Emergent BioSolutions' 5-year Operating Income high stood at $286.8 million for Q4 2021, and its period low was -$292.9 million during Q2 2023.
- In the last 5 years, Emergent BioSolutions' Operating Income had a median value of -$9.5 million in 2024 and averaged -$28.2 million.
- In the last 5 years, Emergent BioSolutions' Operating Income skyrocketed by 89482.76% in 2021 and then plummeted by 223913.04% in 2023.
- Emergent BioSolutions' Operating Income (Quarter) stood at $286.8 million in 2021, then plummeted by 119.28% to -$55.3 million in 2022, then increased by 20.8% to -$43.8 million in 2023, then surged by 78.31% to -$9.5 million in 2024, then soared by 905.26% to $76.5 million in 2025.
- Its Operating Income stands at $76.5 million for Q3 2025, versus $1.6 million for Q2 2025 and $49.9 million for Q1 2025.